XenoPort, Inc. (NASDAQ: XNPT)

XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company, focuses their efforts on developing a portfolio of internally discovered product candidates that leverage the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. The company has directed their focus on developing and commercializing on potential treatments of central nervous system, or CNS, disorders. Their most advanced product candidate, XP13512 (also known as Solzira™), is in the process of being evaluated for the treatment of restless legs syndrome, or RLS, in a Phase 3 clinical program. For further information, visit the Company’s web site at www.xenoport.com.